The U.S. government has admitted that the Federal Aviation Administration and the Army played a role in causing the collision ...

"2025 has been a pivotal year where our commitment to evidence-based clinical innovation was converged with rigorous operational execution," said Clarius CEO Laurent Pelissier. "Achieving ...

Automakers are shifting strategies as Chinese brands rise and regional market needs diverge from regulatory mandates.

Detailed price information for Monte Rosa Therapeutics Inc (GLUE-Q) from The Globe and Mail including charting and trades.

Monte Rosa reports interim Phase 1/2 data showing durable responses and manageable safety for MRT-2359 plus Pfizer's Xtandi ...

The NWRF announced that USA Waste & Recycling and All American Waste as the first services companies to donate to the ...

While we wait patiently for this upside, CUBE is paying us a 5.7%-yielding dividend. Between the yield, low- to ...

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, ...

Investing.com -- Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 3.5% after the company announced positive interim data from its Phase 1/2 clinical study of MRT-2359 in combination with enzalutamide ...

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate ...